Interestingly, the second dose did not significantly further increase the production of IFN-ɣ or IL-2, suggesting that only one dose may be necessary to achieve protection mediated by cellular immunity in COVID-19 recovered HD patients. This evidence concerns the gene IFNA1 and Huntington disease.